Concepts (83)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Reactive | 1 | 2017 | 4 | 0.530 |
Why?
|
| Antitubercular Agents | 1 | 2017 | 265 | 0.440 |
Why?
|
| Syncope | 1 | 2015 | 52 | 0.430 |
Why?
|
| Defibrillators, Implantable | 1 | 2015 | 214 | 0.370 |
Why?
|
| Myocardial Ischemia | 1 | 2015 | 311 | 0.360 |
Why?
|
| Tuberculosis | 1 | 2017 | 555 | 0.330 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2009 | 163 | 0.280 |
Why?
|
| Virus Diseases | 2 | 2020 | 285 | 0.250 |
Why?
|
| Patient Care Management | 1 | 2020 | 61 | 0.160 |
Why?
|
| Pneumonia, Bacterial | 1 | 2020 | 79 | 0.150 |
Why?
|
| Coinfection | 1 | 2020 | 191 | 0.140 |
Why?
|
| Butyrates | 1 | 2018 | 41 | 0.140 |
Why?
|
| Bacteria | 2 | 2020 | 537 | 0.130 |
Why?
|
| Radiation Exposure | 1 | 2018 | 44 | 0.130 |
Why?
|
| Tuberculin Test | 1 | 2017 | 120 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 367 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.110 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 293 | 0.110 |
Why?
|
| Equipment Failure | 1 | 2015 | 131 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2018 | 518 | 0.100 |
Why?
|
| Dexamethasone | 1 | 2015 | 260 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1168 | 0.100 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2015 | 359 | 0.100 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 425 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 644 | 0.090 |
Why?
|
| Nocardia asteroides | 1 | 2012 | 2 | 0.090 |
Why?
|
| Nocardia | 1 | 2012 | 8 | 0.090 |
Why?
|
| Nocardia Infections | 1 | 2012 | 13 | 0.090 |
Why?
|
| Macular Edema | 1 | 2011 | 28 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 2567 | 0.080 |
Why?
|
| Visual Fields | 1 | 2011 | 141 | 0.080 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 836 | 0.080 |
Why?
|
| Diabetic Retinopathy | 1 | 2011 | 86 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 1270 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2128 | 0.070 |
Why?
|
| Cytokines | 1 | 2015 | 1355 | 0.070 |
Why?
|
| Visual Acuity | 1 | 2011 | 536 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2012 | 404 | 0.070 |
Why?
|
| Retina | 1 | 2011 | 461 | 0.070 |
Why?
|
| Inflammation | 1 | 2015 | 1503 | 0.070 |
Why?
|
| Male | 7 | 2018 | 65464 | 0.060 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2009 | 294 | 0.060 |
Why?
|
| Adult | 5 | 2018 | 31755 | 0.060 |
Why?
|
| Middle Aged | 5 | 2018 | 28939 | 0.050 |
Why?
|
| Humans | 9 | 2020 | 132158 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2009 | 1074 | 0.050 |
Why?
|
| Pakistan | 2 | 2015 | 93 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 1908 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 1002 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2017 | 13017 | 0.040 |
Why?
|
| Female | 6 | 2018 | 71430 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 146 | 0.040 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 252 | 0.040 |
Why?
|
| APACHE | 1 | 2018 | 55 | 0.030 |
Why?
|
| Protective Factors | 1 | 2018 | 93 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2018 | 137 | 0.030 |
Why?
|
| Cross Infection | 1 | 2020 | 334 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 678 | 0.030 |
Why?
|
| Radiography | 1 | 2018 | 761 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 1916 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 171 | 0.030 |
Why?
|
| Feces | 1 | 2018 | 725 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1838 | 0.020 |
Why?
|
| Length of Stay | 1 | 2018 | 1403 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2012 | 43 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2012 | 103 | 0.020 |
Why?
|
| Fixation, Ocular | 1 | 2011 | 16 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1638 | 0.020 |
Why?
|
| Aged | 3 | 2018 | 21279 | 0.020 |
Why?
|
| Visual Field Tests | 1 | 2011 | 50 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 11034 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 312 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2018 | 17763 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 1476 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2011 | 467 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 3426 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2012 | 5124 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 6544 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 6924 | 0.010 |
Why?
|
| Infant | 1 | 2015 | 13355 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2015 | 15103 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 21018 | 0.010 |
Why?
|
| Child | 1 | 2015 | 26383 | 0.010 |
Why?
|